Licensing · Global (LMICs) · Announced 16 Nov 2026
Gilead Sciences → Dr. Reddy's Laboratories
Gilead granted Dr. Reddy's a royalty-free voluntary licence to manufacture and supply investigational obeldesivir for Ebola Bundibugyo post-exposure prophylaxis in 127 mainly low- and lower-middle-income countries, including African outbreak countries.
Parties: Gilead Sciences (United States) → Dr. Reddy's Laboratories (India)
- Deal type
- Licensing
- Value
- Royalty-free
- Territory
- 127 countries, primarily low- and lower-middle-income, including all African countries that have reported cases in the current Ebola Bundibugyo outbreak
- Therapeutic area
- Infectious Disease
- Asset
- obeldesivir
- Announced
- 16 Nov 2026
Our analysis
Why this matters
On 16 November 2026 Gilead Sciences announced royalty-free voluntary licensing agreements with Dr. Reddy's Laboratories, Eva Pharma and Ferozsons Laboratories for obeldesivir, an investigational oral antiviral under study for post-exposure prophylaxis (PEP) of Ebola Bundibugyo virus disease (BVD). The licensed territory is 127 countries, primarily low- and lower-middle-income, including all African countries reporting cases in the current outbreak.
The licences were signed ahead of results from EBO-PEP, a partner-led Phase 3 randomised, placebo-controlled trial coordinated by ALIMA. Obeldesivir is not approved anywhere; licensed manufacture and supply depend on clinical data and regulatory authorisations.
The full analysis is free to read with a work email on this page.
Source: Gilead Sciences press release